The antitumour activities induced by pegylated liposomal cytochalasin D in murine models

European Journal of Cancer

Volumn 48, Issue 14, 2012, Pages 2260-2269

  Huang, Feng Ying ^a,b,c   Mei, Wen Li ^b   Li, Yue Nan ^a,b,c   Tan, Guang Hong ^a   Dai, Hao Fu ^b   Guo, Jun Li ^a   Wang, Hua ^a   Huang, Yong Hao ^a   Zhao, Huan Ge ^a   Zhou, Song Lin ^a   Li, Ling ^a   Lin, Ying Ying ^a  

^a HAINAN MEDICAL UNIVERSITY   (China)

^b INSTITUTE OF TROPICAL BIOSCIENCE AND BIOTECHNOLOGY   (China)

^c HAINAN UNIVERSITY   (China)

Author keywords

Apoptosis; Cytochalasin D; Pegylated liposome; Tumour angiogenesis

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; CISPLATIN; CYTOCHALASIN D; LIPOSOME; WATER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CARCINOGENESIS; CELL PROLIFERATION; COLORECTAL CARCINOMA; CONTROLLED STUDY; DRUG HALF LIFE; DRUG INHIBITION; DRUG TARGETING; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; LIVER CELL CARCINOMA; MELANOMA B16; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; SURVIVAL TIME; TUMOR GROWTH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BIOLOGICAL AVAILABILITY; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL PROLIFERATION; CHEMISTRY, PHARMACEUTICAL; COLORECTAL NEOPLASMS; CYTOCHALASIN D; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; INJECTIONS, INTRAVENOUS; LIPOSOMES; LIVER NEOPLASMS, EXPERIMENTAL; MALE; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; POLYETHYLENE GLYCOLS; SOLUBILITY; TISSUE DISTRIBUTION; TUMOR BURDEN;

EID: 84865483514     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.12.018     Document Type: Article

References (46)

1. E.A. Papakonstanti, and C. Stournaras Cell responses regulated by early reorganization of actin cytoskeleton FEBS Lett 582 2008 2120 2127
2. G. Kustermans, J. Piette, and S. Legrand-Poels Actin-targeting natural compounds as tools to study the role of actin cytoskeleton in signal transduction Biochem Pharmacol 76 2008 1310 1322
3. E.M. Bonder, and M.S. Mooseker Direct electron microscopic visualization of barbed end capping and filament cutting by intestinal microvillar 95-kdalton protein (villin): a new actin assembly assay using the Limulus acrosomal process J Cell Biol 96 1983 1097 1107
4. E.M. Bonder, D.J. Fishkind, and M.S. Mooseker Direct measurement of critical concentrations and assembly rate constants at the two ends of an actin filament Cell 34 1983 491 501
5. E.D. Goley, and M.D. Welch The ARP2/3 complex: an actin nucleator comes of age Nat Rev Mol Cell Biol 7 2006 713 726
6. T.D. Pollard, L. Blanchoin, and R.D. Mullins Molecular mechanisms controlling actin filament dynamics in nonmuscle cells Annu Rev Biophys Biomol Struct 29 2000 545 576
7. M. Ailenberg, and M. Silverman Cytochalasin D disruption of actin filaments in 3T3 cells produces an anti-apoptotic response by activating gelatinase A extracellularly and initiating intracellular survival signals Biochim Biophys Acta 1593 2003 249 258
8. M.G. Levee, M.I. Dabrowska, and J.L. Lelli Actin polymerization and depolymerization during apoptosis in HL-60 cells Am J Physiol 271 1996 C1981 C1992
9. T. Seufferlein, and E. Rozengurt Lysophosphatidic acid stimulates tyrosine phosphorylation of focal adhesion kinase, paxillin, and p130. Signaling pathways and cross-talk with platelet-derived growth factor J Biol Chem 269 1994 9345 9351
10. S.M. Frisch, and H. Francis Disruption of epithelial cell-matrix interactions induces apoptosis J Cell Biol 124 1994 619 626
11. T. Udagawa, J. Yuan, D. Panigrahy, and Y.H. Chang Cytochalasin E, an epoxide containing Aspergillus-derived fungal metabolite, inhibits angiogenesis and tumor growth J Pharmacol Exp Ther 294 2000 421 427
12. P.F. Bousquet, L.A. Paulsen, and C. Fondy Effects of cytochalasin B in culture and in vivo on murine Madison 109 lung carcinoma and on B16 melanoma Cancer Res 50 1990 1431 1439
13. J.A. Cooper Effects of cytochalasin and phalloidin on actin J Cell Biol 105 1987 1473 1478
14. M. Rijtema, D. Mosig, and A. Drukker The effects of dimethyl sulfoxide on renal function of the newborn rabbit Biol Neonate 76 1999 355 361
15. L.F. Marshall, P.E. Camp, and S.A. Bowers Dimethyl sulfoxide for the treatment of intracranial hypertension: a preliminary trial Neurosurgery 14 1984 659 663
16. R.S. Muther, and W.M. Bennett Effects of dimethyl sulfoxide on renal function in man JAMA 244 1980 2081 2083
17. T.M. Allen, and P.R. Cullis Drug delivery systems: entering the mainstream Science 303 2004 1818 1822
18. G. Batist, G. Ramakrishnan, and C.S. Rao Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 2001 1444 1454
19. F. Yuan, M. Dellian, and D. Fukumura Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size Cancer Res 55 1995 3752 3756
20. J.M. Harris, and R.B. Chess Effect of pegylation on pharmaceuticals Nat Rev Drug Discov 2 2003 214 221
21. Z.P. Yuan, L.J. Chen, and L.Y. Fan Liposomal quercetin efficiently suppresses growth of solid tumors in murine models Clin Cancer Res 12 2006 3193 3199
22. J.M. Malecki, A. Bentke, and B. Ostrowska LY294002 and olomoucine synergize in promoting death of melanoma cells through activation of caspase-3 and apoptosis Melanoma Res 20 2010 52 58
23. G.H. Tan, Y.Q. Wei, and L. Tian Active immunotherapy of tumors with a recombinant xenogeneic endoglin as a model antigen Eur J Immunol 34 2004 2012 2021
24. J. Hoffmann, M. Schirner, and A. Menrad A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells Cancer Res 57 1997 3847 3851
25. M.L. Bednarek, J.E. Speich, and A.S. Miner Active tension adaptation at a shortened arterial muscle length: inhibition by cytochalasin-D Am J Physiol Heart Circ Physiol 300 2011 H1166 H1173
26. G.J. Murphy, T.W. Johnson, and M.H. Chamberlain Short- and long-term effects of cytochalasin D, paclitaxel and rapamycin on wall thickening in experimental porcine vein grafts Cardiovasc Res 73 2007 607 617
27. K.J. Salu, J.M. Bosmans, and Y. Huang Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model Cardiovasc Res 2006 69536 69544
28. J.I. Chao, and H.F. Liu The blockage of survivin and securin expression increases the cytochalasin B-induced cell death and growth inhibition in human cancer cells Mol Pharmacol 69 2006 154 164
29. 2+ currents via cofilin-activated depolymerization of F-actin in guinea-pig cardiomyocytes J Physiol 537 2001 363 370
30. Y.Y. Fu, E. Sibley, and S.C. Tang Transient cytochalasin-D treatment induces apically administered rAAV2 across tight junctions for transduction of enterocytes J Gen Virol 89 2008 3004 3008
31. J. Miyazaki, H. Nishiyama, and I. Yano The therapeutic effects of R8-liposome-BCG-CWS on BBN-induced rat urinary bladder carcinoma Anticancer Res 31 2011 2065 2071
32. G.J. Fetterly, T.H. Grasela, and J.W. Sherman Pharmacokinetic/ pharmacodynamic modeling and simulation of neutropenia during phase I development of liposome-entrapped paclitaxel Clin Cancer Res 14 2008 5856 5863
33. M. Nakase, M. Inui, and K. Okumura P53 gene therapy of human osteosarcoma using a transferrin-modified cationic liposome Mol Cancer Ther 4 2005 625 631
34. C.M. Lee, T. Tanaka, and T. Murai Novel chondroitin sulfate-binding cationic liposomes loaded with cisplatin efficiently suppress the local growth and liver metastasis of tumor cells in vivo Cancer Res 62 2002 4282 4288
35. P. Tardi, E. Choice, and D. Masin Liposomal encapsulation of topotecan enhances anticancer efficacy in murine and human xenograft models Cancer Res 60 2000 3389 3393
36. D.L. Emerson, R. Bendele, and E. Brown Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan Clin Cancer Res 6 2000 2903 2912
37. M. Campoli, R. Ferris, and S. Ferrone Immunotherapy of malignant disease with tumor antigen-specific monoclonal antibodies Clin Cancer Res 16 2010 11 20
38. M. Pennati, M. Folini, and N. Zaffaroni Targeting survivin in cancer therapy: fulfilled promises and open questions Carcinogenesis 28 2007 1133 1139
39. R. Koschny, H. Holland, and J. Sykora Bortezomib sensitizes primary human astrocytoma cells of WHO grades I to IV for tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis Clin Cancer Res 13 2007 3403 3412
40. K. Shchors, and G. Evan Tumor angiogenesis: cause or consequence of cancer? Cancer Res 67 2007 7059 7061
41. A. Albini, F. Tosetti, and R. Benelli Tumor inflammatory angiogenesis and its chemoprevention Cancer Res 65 2005 10637 10641
42. M.I. Dorrell, E. Aguilar, and L. Scheppke Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis Proc Nat Acad Sci U.S.A. 104 2007 967 972
43. G.H. Tan, L. Tian, and Y.Q. Wei Combination of low-dose cisplatin and recombinant xenogeneic endoglin as a vaccine induces synergistic antitumor activities Int J Cancer 112 2004 701 706
44. G. Giaccone, J.L. Gonzalez-Larriba, and A.T. van Oosterom Combination therapy with gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, gemcitabine and cisplatin in patients with advanced solid tumors Ann Oncol 15 2004 831 838
45. S.N. Rubtsova, R.V. Kondratov, and P.B. Kopnin Disruption of actin microfilaments by cytochalasin D leads to activation of p53 FEBS Lett 430 1998 353 357
46. K. Katagiri, and S. Matsuura Antitumor activity of cytochalasin D J Antibiot (Tokyo) 24 1971 722 723